Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Proof of Principle Program - Phase I

University of Toronto

$149,949.00

Peptide therapeutics for preventing retinal ganglion cell apoptosis

EF 2014-15

Résumé
Glaucoma is the second leading cause of blindness, affecting at least 300,000 Canadians, and over 67,000,000 people worldwide. Retinal Ganglion cell (RGC) death is a major cause of visual impairment in optic neuropathies including glaucoma, AMD, diabetic retinopathy, uveoretinitis and vitreo-retinopathy. Glaucoma is a disease in which RGCs die by apoptosis (programmed cell death), leading to peripheral vision loss and eventually blindness. Glaucoma, commonly characterized by an increase in intraocular pressure, is treated by ocular hypotensive drugs such as latanoprost. Despite the advent and therapeutic use of these drugs, vision loss as a result of RGC apoptosis and optic nerve atrophy continues, resulting in blindness. Several animal models of RGC apoptosis are widely used to test potential therapeutics for preventing RGC apoptosis in visual disease. These include optic nerve transection (axotomy), ophthalmic artery ligation (stroke/ischemia), and models of elevated intraocular pressure. Using several of these models, we have discovered multiple peptides that act as competitive inhibitors of protein-protein interactions that are necessary for RGC apoptosis. We are now moving forward with our two most promising clinical candidates, peptides that block the C-termininal interactions of PTEN phosphatase and the potassium channel Kv2.1.
Programme
Proof of Principle Program - Phase I
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
315101
Name
Koeberle Paulo D
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
Peptide therapeutics for preventing retinal ganglion cell apoptosis
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$149,949
Cihrequipment2
$0
Programname2
Proof of Principle Program - Phase I
Keyworddelim
Apoptosis; Glaucoma; Peptide; Retinal Ganglion Cell; Visual Disease
Abstract
Glaucoma is the second leading cause of blindness, affecting at least 300,000 Canadians, and over 67,000,000 people worldwide. Retinal Ganglion cell (RGC) death is a major cause of visual impairment in optic neuropathies including glaucoma, AMD, diabetic retinopathy, uveoretinitis and vitreo-retinopathy. Glaucoma is a disease in which RGCs die by apoptosis (programmed cell death), leading to peripheral vision loss and eventually blindness. Glaucoma, commonly characterized by an increase in intraocular pressure, is treated by ocular hypotensive drugs such as latanoprost. Despite the advent and therapeutic use of these drugs, vision loss as a result of RGC apoptosis and optic nerve atrophy continues, resulting in blindness. Several animal models of RGC apoptosis are widely used to test potential therapeutics for preventing RGC apoptosis in visual disease. These include optic nerve transection (axotomy), ophthalmic artery ligation (stroke/ischemia), and models of elevated intraocular pressure. Using several of these models, we have discovered multiple peptides that act as competitive inhibitors of protein-protein interactions that are necessary for RGC apoptosis. We are now moving forward with our two most promising clinical candidates, peptides that block the C-termininal interactions of PTEN phosphatase and the potassium channel Kv2.1.
Competitiondate
201409
Approvedterm2
1 yr 0 mth
Pinamesdelim
Koeberle, Paulo D
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $149,949~ $0~